-
consortium. Your academic supervision will be provided by Prof. Timo De Groof and Prof. Nick Devoogdt. This doctoral project focuses on developing GPRC5B-targeting nanobodies for use as research tools
-
investigated as drug targets. The aim of the project is to understand how the orphan receptor is activated and signals, develop high-throughput screening assays and identify drug-like modulators. You will use
-
megalencephalic leukoencephalopathy with subcortical cysts (MLC). The project combines behavioural and neurological phenotyping with the development of an automated EEG analysis pipeline. You will use
-
organisation is the University of York, UK. The selected candidate will be employed by the University of York and become part of the POLARIS consortium, with academic supervision and disease-specific expertise
-
disease (VWM) and metachromatic leukodystrophy (MLD). You will investigate the efficacy and safety of AAV gene therapy in VWM and MLD mouse models. In addition, you will use genome-editing approaches
-
biological reference point for identifying disease-specific biomarkers. A central part of the project is the use of iPSC-derived models, including oligodendrocytes, astrocytes, neurons and myelinating
-
is the Medicines Evaluation Board (MEB) in Utrecht, the Netherlands. You will be employed by the MEB and embedded in the POLARIS consortium. You will be supervised by Dr Marjon Pasmooij and work
-
machine-learning approaches. Established markers such as neurofilament light chain (NfL) and GFAP will provide a biological reference point for identifying disease-specific biomarkers. A central part of the
-
countries (HIC). The airm of this PhD project is to understand how E. coli colonization contributes tot he risk of diarrheal disease and infections with AMR and use this knowledge to design interventions
-
in the POLARIS consortium and work with experts in leukodystrophy, paediatric neurology, developmental psychopathology, resilience research and digital quality-of-life assessment. Leukodystrophies can